Negative symptoms are a significant barrier to successful functional outcome and recovery in individuals with schizophrenia and their management is not unproblematic. Reboxetine is a norepinephrine reuptake inhibitor (NRI)
RESULTS:
According to the findings, 76% of patients in the target group showed some positive response to reboxetine compared with 24% in the control group .
CONCLUSION:
Reboxetine, as an adjuvant to haloperidol, may have a helpful effect on the deficit syndrome of schizophrenia.